Skip to main content
Clinical Trials/ITMCTR2000003977
ITMCTR2000003977
Not yet recruiting
Phase 1

Development and Evaluation of Technical Standards for Diagonosis and Treatment of Integartive Medicine for Insomnia

Guangdong Provincial Hospital of Chinese Medicine0 sitesTBD
ConditionsInsomnia

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Insomnia
Sponsor
Guangdong Provincial Hospital of Chinese Medicine
Status
Not yet recruiting
Last Updated
3 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
3 years ago
Study Type
Interventional study
Sex
All

Investigators

Sponsor
Guangdong Provincial Hospital of Chinese Medicine

Eligibility Criteria

Inclusion Criteria

  • 1\. Adults diagnosed with insomnia using the DSM\-5 and ICSD\-3;
  • 2\. Aged 18 to 65 years;
  • 3\. Pittsburgh Sleep Quality Index (PSQI) \>7 during the screening period and at baseline;
  • 4\. Insomnia severity index (ISI)\>7 during the screening period and at baseline;;
  • 5\. Stable vital signs with certain expression and cognitive ability;
  • 6\. Volunteer to participate in this clinical trial and sign an informed consent form.

Exclusion Criteria

  • 1\. Participants with other related medical history that may affect sleep including narcolepsy, circadian rhythm sleep disorder, sleepwalking, sleep\-related breathing disorder, obstructive or central sleep apnea syndrome, restless legs syndrome, etc.;
  • 2\. Participants with sever mental illnesses or emotional and behavior disorder disorder (such as schizophrenia, suicidal tendency or suicide history) in the past year, or long\-term use of central nervous system depressant or stimulant drugs;
  • 3\. Insomnia caused by other conditions in the past month, such as pain, fever, cough, surgery, interference from the external environment, etc.;
  • 4\. Liver function AST and ALT exceed the upper limit of normal reference value by 1\.5 times, or Scr exceeds the upper limit of normal reference value.
  • 5\. Participants with severe cardiovascular, lung, liver, kidney, endocrine or central nervous system diseases;
  • 6\. Drug and alcohol abuse or dependence;
  • 7\. Participants with allergic reaction to the test drug or its ingredients;
  • 8\. Pregnant or lactating women, women of childbearing age who cannot take contraceptive measures during the trial;
  • 9\. Participants participate in other drug clinical trials within the past month;
  • 10\. Researchers consider the participant is inappropriate to participate in this clinical trial.

Outcomes

Primary Outcomes

Not specified

Similar Trials